DelveInsight’s “Autistic Disorder Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Autistic Disorder pipeline landscape. It covers the Autistic Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Autistic Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Autistic Disorder Pipeline @ https://www.delveinsight.com/sample-request/autistic-disorder-pipeline-insight

Key Takeaways from the Autistic Disorder Pipeline Report

• On May 19, 2026- MapLight Therapeutics conducted a study that will enroll approximately 150 adolescent and adult subjects with ASD. The primary objective is to evaluate the efficacy of ML-004 compared with placebo in the improvement of social communication deficits in subjects with ASD.
• On May 13, 2026- Otsuka Pharmaceutical Development & Commercialization Inc. conducted a study will compare the effectiveness (how well the drug works) of aripiprazole, flexibly dosed with a placebo, in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
• On May 11, 2026- Karuna Therapeutics Inc. initiated a phase 3 study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively
• DelveInsight’s Autistic Disorder pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Autistic Disorder treatment.
• The leading Autistic Disorder Companies such as AbbVie, Yamo Pharmaceuticals, Stalicla SA, Vanda Pharmaceuticals, Paxmedica, SciSparc, Scioto Biosciences, Inc., Hoffmann-La Roche, ACADIA Pharmaceuticals Inc., Neurotech International, Neuren Pharmaceuticals, MapLight Therapeutics, Jazz Pharmaceuticals, Axial Therapeutics Inc. and others.
• Promising Autistic Disorder Pipeline Therapies such as Aripiprazole, Sapropterin, Kuvan®, Fluoxetine, Atomoxetine, Terpenes-Enriched CBD-Predominant Oil, L1-79, Midomafetamine HCl, Cannabidivarin and others.

Stay ahead with the most recent pipeline outlook for Autistic Disorder @ Autistic Disorder Treatment Drugs

The Autistic Disorder Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Autistic Disorder Pipeline Report also highlights the unmet needs with respect to Autistic Disorder.

Autistic Disorder Overview

Autistic disorder, also known as Autism Spectrum Disorder (ASD), encompasses a spectrum of neurodevelopmental disabilities. ASD is a complicated neurodevelopmental disorder that is characterized by behavioral and psychological problems in children. These children become distressed when their surrounding environment changes because their adaptive capabilities are minimal. The symptoms are present from early childhood and affect daily functioning. Children with ASD have co-occurring language problems, intellectual disabilities, and epilepsy at higher rates than the general population.

Autistic Disorder Emerging Drugs Profile

• Cariprazine: AbbVie

Cariprazine is an atypical antipsychotic. It is thought to be effective due to its partial agonist activity at the dopamine D2 receptor and serotonin 5HT1A receptor and its antagonism at the serotonin 5HT2A receptor. Additionally, Cariprazine has a high affinity for dopamine D3 receptors, acting as a partial agonist at D3 receptors. Cariprazine is primarily metabolized by CYP3A4 into Desmethyl Cariprazine (DCAR), and DCAR is then further metabolized by CYP3A4 into Didesmethyl Cariprazine (DDCAR). DCAR and DDCAR both display similar pharmacological potencies as Cariprazine. Currently, the drug is in the Phase III stage of its development for the treatment of Autistic Disorder.

• L1-79: Yamo Pharmaceuticals

L1-79 is a novel therapy that targets the core symptoms of autism. Previous experience with open-label administration of L1-79 in patients with autism demonstrated that L1-79 is a well-tolerated oral treatment that has the potential to improve the core symptoms of autism. In a recently completed Phase II study, multiple independent efficacy measures assessed using commonly accepted and validated psychometric tests demonstrated positive trends supporting improvements in the target core symptom domains affected by autism, especially social domains, despite a short treatment period and small number of patients. This data supported the granting of a Fast Track Designation by the Food and Drug Administration (FDA) in May of 2018. Currently, the drug is in the Phase II stage of its development for the treatment of Autistic Disorder.

• STP1: Stalicla SA

STP1 is a fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide) shown to be a top drug match for a subgroup of patients with autism spectrum disorder (ASD) called phenotype 1. STP1 has completed phase 1b trials showing strong safety and tolerability, improvements in brain function for executive function and memory and improved autism severity scores. Currently, the drug is in Phase II stage of its development for the treatment of autistic disorder.

Explore groundbreaking therapies and clinical trials in the Autistic Disorder Pipeline @ New Autistic Disorder Drugs

The Autistic Disorder Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Autistic Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Autistic Disorder Treatment.
• Autistic Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Autistic Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Autistic Disorder market

Autistic Disorder Companies

AbbVie, Yamo Pharmaceuticals, Stalicla SA, Vanda Pharmaceuticals, Paxmedica, SciSparc, Scioto Biosciences, Inc., Hoffmann-La Roche, ACADIA Pharmaceuticals Inc., Neurotech International, Neuren Pharmaceuticals, MapLight Therapeutics, Jazz Pharmaceuticals, Axial Therapeutics Inc. and others.

Autistic Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Autistic Disorder Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Autistic Disorder Market Drivers and Barriers

Scope of the Autistic Disorder Pipeline Report

• Coverage- Global
• Autistic Disorder Companies- AbbVie, Yamo Pharmaceuticals, Stalicla SA, Vanda Pharmaceuticals, Paxmedica, SciSparc, Scioto Biosciences, Inc., Hoffmann-La Roche, ACADIA Pharmaceuticals Inc., Neurotech International, Neuren Pharmaceuticals, MapLight Therapeutics, Jazz Pharmaceuticals, Axial Therapeutics Inc. and others.
• Autistic Disorder Pipeline Therapies- Aripiprazole, Sapropterin, Kuvan®, Fluoxetine, Atomoxetine, Terpenes-Enriched CBD-Predominant Oil, L1-79, Midomafetamine HCl, Cannabidivarin and others.
• Autistic Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Autistic Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Autistic Disorder Companies, Key Products, and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Autistic Disorder: Overview
4. Pipeline Therapeutics
5. Therapeutics Assessment
6. Autistic Disorder– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Cariprazine: AbbVie
9. Mid Stage Products (Phase II)
10. L1-79: Yamo Pharmaceuticals
11. Early Stage Products (Phase I)
12. STP1: Stalicla SA
13. Preclinical and Discovery Stage Products
14. Inactive Products
15. Autistic Disorder Key Companies
16. Autistic Disorder Key Products
17. Autistic Disorder- Unmet Needs
18. Autistic Disorder- Market Drivers and Barriers
19. Autistic Disorder- Future Perspectives and Conclusion
20. Autistic Disorder Analyst Views
21. Autistic Disorder Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/autistic-disorder-pipeline-insight